| A taxonomy of model structures for economic evaluation of health technologies A Brennan, SE Chick, R Davies Health economics 15 (12), 1295-1310, 2006 | 650 | 2006 |
| Modeling using discrete event simulation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force–4 J Karnon, J Stahl, A Brennan, JJ Caro, J Mar, J Möller Medical decision making 32 (5), 701-711, 2012 | 609 | 2012 |
| Screening for type 2 diabetes: literature review and economic modelling N Waugh, G Scotland, P McNamee, M Gillett, A Brennan, E Goyder, ... HEALTH TECHNOLOGY ASSESSMENT-SOUTHAMPTON- 11 (17), 2007 | 424 | 2007 |
| Effects of minimum unit pricing for alcohol on different income and socioeconomic groups: a modelling study J Holmes, Y Meng, PS Meier, A Brennan, C Angus, A Campbell-Burton, ... The Lancet 383 (9929), 1655-1664, 2014 | 411 | 2014 |
| Estimated effect of alcohol pricing policies on health and health economic outcomes in England: an epidemiological model RC Purshouse, PS Meier, A Brennan, KB Taylor, R Rafia The Lancet 375 (9723), 1355-1364, 2010 | 343 | 2010 |
| Estimating multiparameter partial expected value of perfect information from a probabilistic sensitivity analysis sample: a nonparametric regression approach M Strong, JE Oakley, A Brennan Medical Decision Making 34 (3), 311-326, 2014 | 292 | 2014 |
| Delivering the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cost effectiveness … M Gillett, HM Dallosso, S Dixon, A Brennan, ME Carey, MJ Campbell, ... Bmj 341, 2010 | 277 | 2010 |
| Accurate, practical and cost-effective assessment of carotid stenosis in the UK. JM Wardlaw, FM Chappell, M Stevenson, E De Nigris, S Thomas, J Gillard, ... Health Technology Assessment (Winchester, England) 10 (30), iii-iv, ix, 2006 | 274 | 2006 |
| Policy options for alcohol price regulation: the importance of modelling population heterogeneity PS Meier, R Purshouse, A Brennan Addiction 105 (3), 383-393, 2010 | 255 | 2010 |
| Modelling in health economic evaluation: What is its place? What is its value? A Brennan, R Akehurst Pharmacoeconomics 17, 445-459, 2000 | 234 | 2000 |
| Non-pharmacological interventions to reduce the risk of diabetes in people with impaired glucose regulation: a systematic review and economic evaluation M Gillett, P Royle, A Snaith, G Scotland, AS Poobalan, M Imamura, ... Health technology assessment 16 (33), 2012 | 216 | 2012 |
| Should patients have a greater role in valuing health states? J Brazier, R Akehurst, A Brennan, P Dolan, K Claxton, C McCabe, ... Applied health economics and health policy 4, 201-208, 2005 | 216 | 2005 |
| Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK A Brennan, N Bansback, A Reynolds, P Conway Rheumatology 43 (1), 62-72, 2004 | 209 | 2004 |
| Estimated effects of different alcohol taxation and price policies on health inequalities: a mathematical modelling study PS Meier, J Holmes, C Angus, AK Ally, Y Meng, A Brennan PLoS medicine 13 (2), e1001963, 2016 | 194 | 2016 |
| Home telemonitoring or structured telephone support programmes after recent discharge in patients with heart failure: systematic review and economic evaluation. A Pandor, P Thokala, T Gomersall, H Baalbaki, JW Stevens, J Wang, ... Health Technology Assessment (Winchester, England) 17 (32), 1, 2013 | 193 | 2013 |
| Using mixed treatment comparisons and meta‐regression to perform indirect comparisons to estimate the efficacy of biologic treatments in rheumatoid arthritis RM Nixon, N Bansback, A Brennan Statistics in medicine 26 (6), 1237-1254, 2007 | 187 | 2007 |
| Trend analysis and modelling of gender‐specific age, period and birth cohort effects on alcohol abstention and consumption level for drinkers in G reat B ritain using the G … Y Meng, J Holmes, D Hill‐McManus, A Brennan, PS Meier Addiction 109 (2), 206-215, 2014 | 160 | 2014 |
| Calculating partial expected value of perfect information via Monte Carlo sampling algorithms A Brennan, S Kharroubi, A O'hagan, J Chilcott Medical Decision Making 27 (4), 448-470, 2007 | 160 | 2007 |
| Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden NJ Bansback, A Brennan, O Ghatnekar Annals of the rheumatic diseases 64 (7), 995-1002, 2005 | 159 | 2005 |
| Modelling the cost effectiveness of TNF-α antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry A Brennan, N Bansback, R Nixon, J Madan, M Harrison, K Watson, ... Rheumatology 46 (8), 1345-1354, 2007 | 145 | 2007 |
Petra MeierProfessor of Public Health, University of GlasgowVerified email at glasgow.ac.uk
